重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对严重脓毒血症患者ss-CRP及TNF-α的影响

Influence of Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein on Super Sensitive C-Reactive Protein and Tumor Necrosis Factor-α in Patients With Severe Sepsis

目的探讨重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对严重脓毒血症患者细胞因子的影响。方法将42例严重脓毒血症患者随机分为对照组和治疗组,其中对照组17例,治疗组25例,两组均行常规抗感染和病因治疗。治疗组用1毫升注射用水溶解50 mg重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白,皮下注射,隔日一次;分别于治疗前、注射后7天后测试ss-CRP及TNF-α。结果与对照组相比,治疗组应用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白后ss-CRP及TNF-α均明显降低,P<0.05。结论重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白可降低严重脓毒血症患者TNF-α的水平,从而达到保护器官的作用。

Objective To evaluate the influence of recombinant human tumor necrosis factor-α receptorⅡ： IgG Fc fusion protein（rhTNFR： Fc） on super sensitive C-reactive protein（ss-CRP） and human tumor necrosis factor-α（TNF-α）in patients with severe sepsis.Methods Forty-two patients were randomly divided into the control group（17 cases） and treatment group（25 cases）.Antibiotics and etiological treatment were conventionally given to both groups.In addition,rhTNFR,50 mg,dissolved in 1 ml water for injection,was administered subcutaneously to the treatment group every other day.The levels of ss-CRP and TNF-α were measured before treatment and seven days after treatment.Results The levels of both ss-CRP and TNF-α in the treatment group were significantly lower than those in the control group（P0.05）.Conclusions rhTNFR can reduce the level of TNF-α in patients with severe sepsis and protect the internal organs.